HeartFlow

HeartFlow

HTFL
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

HTFL · Stock Price

USD 29.98-0.01 (-0.03%)
Market Cap: $2.5B

Historical price data

Market Cap: $2.5BPipeline: 3 drugsPatents: 20Founded: 2010Employees: 500-1000HQ: San Francisco, United States

Overview

HeartFlow's mission is to transform coronary artery disease from a leading cause of death into a proactively managed chronic condition. The company has achieved remarkable commercial success, with its technology deployed in over 1,800 institutions, used on 600,000+ patients, and secured near-universal U.S. insurance reimbursement. Its strategy centers on expanding its AI-powered platform from a diagnostic tool into a comprehensive, longitudinal management system for CAD, leveraging a vast and growing clinical evidence base.

Cardiovascular DiseaseCoronary Artery Disease

Technology Platform

AI-powered software platform that converts standard coronary CT angiography scans into personalized 3D models, simulating blood flow (FFR CT) and quantifying plaque to provide integrated anatomical and physiological insights.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
EvolocumabCoronary Artery DiseaseApproved
Rosuvastatin 40mg + PlaceboCoronary Artery DiseasePre-clinical
High intensity lipid loweringCoronary Artery DiseasePre-clinical